The Data-Driven Playbook for Commercial Due Diligence

Most private equity (PE) commercial due diligence is conducted in the same place the deal was originated: management presentations and market research reports. You hear the company's story of their revenue. You read an analyst's view of the TAM. You see the headline metrics. Then you form a view.

The transaction data tells a different story. Not a worse story about the business necessarily, but a more specific one. And the specific story is almost always more useful than the headline narrative when you're determining whether to pay 7x or 9x and what value creation is actually achievable.

Where the Guessing Happens

Standard CDD processes rely heavily on two inputs that are structurally unreliable.

Management interviews are not unreliable because management is dishonest. They're unreliable because management's narrative naturally emphasizes the most recent positive trends. A company that had a difficult 2022 and recovered in 2023 will present 2023 as the baseline story. The 2022 data exists in the transaction records. It doesn't exist prominently in the management presentation.

Market research reports tell you about TAM and competitive position. They don't tell you about this company's actual penetration of its addressable market, which cohorts of customers have churned and why, or whether the current growth rate is sustainable given the ideal customer profile (ICP) concentration in the existing base.

The place where guessing produces the most expensive errors is in net revenue retention (NRR) assessment. Acquirers who accept a headline NRR without cohort analysis regularly overpay for businesses whose revenue is more fragile than the headline suggests. A company with 103% blended NRR and a single cohort driving 40% of expansion is a different business than a company with 103% NRR distributed across cohorts. The former has concentration risk that belongs in the enterprise value calculation.

What the Transaction Data Actually Reveals

When you build the price waterfall from actual transaction records, you find things that don't appear in the CRM discount fields. Off-invoice concessions, free implementation periods, extended payment terms, and bundled professional services hours show up in the contract and invoice data. In most mid-market acquisitions, the fully loaded pocket price is 8 to 18 points below the headline discount figure management reports.

Cohort-level NRR analysis tells you whether expansion is being driven by organic value realization or by active upsell motion that will require ongoing sales investment to sustain. It also tells you which acquisition channels generate the highest-NRR cohorts, which is one of the most important inputs for post-acquisition go-to-market (GTM) investment allocation.

ICP concentration analysis surfaces the segment risk that headline revenue numbers obscure. A $45M annual recurring revenue (ARR) SaaS company with 60% of revenue from accounts in a single vertical is structurally different from one with 60% of revenue distributed across three verticals. Pricing power, competitive risk, and expansion TAM are all different. The transaction data makes this visible. The management presentation doesn't foreground it.

The Framework

A data-driven commercial due diligence process covers three analytical layers.

Layer 1: Price waterfall from source documents. Don't rely on CRM discount fields. Pull the contracts, amendments, and invoices for the trailing 24 months. Build the waterfall from list price through all off-invoice adjustments to pocket price. This takes more time than a report review. It produces the only accurate picture of pricing health you can get before acquisition.

Layer 2: Cohort analysis by acquisition channel, vintage, and deal size. Segment NRR into at least four cohorts: acquisition year (two most recent), acquisition channel (inbound vs. outbound), and deal size band. Look for divergence between cohorts. The cohort with the worst NRR will tell you where the commercial model breaks down and what it will cost to fix.

Layer 3: ICP quality scoring against the sales pipeline. If the transaction data shows that in-ICP customers have 15-point higher NRR than out-of-ICP customers, and 35% of the current pipeline is out-of-ICP, you have a forward-looking revenue quality problem that isn't in the headline ARR figures.

The Failure Case

A growth equity firm acquired a marketing technology company at $52M ARR at 7.8x entry multiple. Headline NRR was 107%. The commercial diligence had been conducted via management presentations and one round of customer reference calls.

Post-close cohort analysis revealed that the 107% NRR was driven by five accounts representing 31% of ARR. Those accounts were each in an expansion phase that the product team confirmed was near saturation. The remaining 69% of the base had NRR of 94%.

Before: Headline 107% NRR at entry, 7.8x multiple, no cohort analysis in diligence.

After: Post-close reforecast showed the exit ARR projections were overstated by 18%. Value creation plan had to be rebuilt from a lower base. The five expansion accounts did plateau within 18 months as predicted by the product team.

What to Do This Week

If you're in diligence on a software business right now, ask for the NRR broken down by acquisition cohort for the last three years. If the seller can't produce that analysis within 48 hours, it either doesn't exist in a usable form or the cohort story is worse than the headline.

Either finding is information you needed before you set valuation.

Assess Your Commercial Health for a structured framework you can run on your own business or your portfolio companies.

For the broader context of PE value creation strategy, see Why Your Instincts Are Wrong About Private Equity Value Creation.